Oncorus
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50 Hampshire St Ste 401, Cambridge, Mass...Phone Number
(857) 320-6400Website
www.oncorus.comRevenue
$18.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Oncorus
At Oncorus, the company is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. The company is advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on the company's Herpes Simplex Virus (HSV) Platform and selectively self-amplifying viral RNA (vRNA)/ lipid nanoparticle (LNP) Immunotherapy Platform. Designed to deliver next-generation viral immunotherapy impact, the company's HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. The company's lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. The company's pioneering selectively self-amplifying vRNA IRead more
Oncorus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncorus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Oncorus had a recent Job posting/layoffs
Check out if Oncorus is spiking on competitors!
Product Launch: Get notified when Oncorus launches new products
Congratulate Masked Content for being promoted to Masked Content at Oncorus
Earning: See what the market has to say on Oncorus recently announced quarterly report
Check if Oncorus has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Oncorus has new funding data
Oncorus, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Oncorus
Compare insights from companies similar to Oncorus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$14.6M
51-200
Private
<$5M
2007
MM
Matthew MessinghamManaging Director, Specialty Department & Landscape Maintenance Services
Company Profile Activity
Activity Insights
Oncorus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncorus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncorus.
Oncorus financials insights
Gather financial insights about Oncorus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$57M
2019
Series B
$79.5M
2020
Stock Offering
$87M
2022
Debt
$20M
Oncorus Tech Stack
A closer look at the technologies used by Oncorus
Most Recent Scoops
Facilities Relocation / Expansion
Oncorus is planning to move offices in June 2024. The move will impact approximately 11 employees at the existing office located at 50 Hampshire St, Cambridge, MA.
Facilities Relocation/Expansion
Left Company
Executive Move
Lateral Move
Executive Move
Left Company
Executive Move
Layoffs
Layoffs
Oncorus News & Media
Oncorus Announces Layoff
ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously... Read More The post Oncorus Announces Layoff appeared first on citybiz.Oncorus Announces Workforce Reduction Plan
ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncorus
Sign Up For FreeTo access detailed company insights
At Oncorus, the company is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. The company is advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on the company's Herpes... Read More
